TapImmune Inc (TPIV)

4.42
0.05 1.13
OTC : Health Care
Prev Close 4.47
Open 4.40
Day Low/High 4.40 / 4.60
52 Wk Low/High 3.32 / 9.83
Volume 5.62K
Avg Volume 32.50K
Exchange OTC
Shares Outstanding 8.38M
Market Cap 39.05M
EPS -58.40
Div & Yield N.A. (N.A)

Latest News

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

Initiation of Company-Sponsored Phase 2 Clinical Trials will start early 2017

MicroCap Review Magazine Fall 2016 Issue Now Available

MicroCap Review Magazine Fall 2016 Issue Now Available

The Digital Issue of the Fall 2016 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com

TapImmune Appoints Michael J. Loiacono As Chief Financial Officer

TapImmune Appoints Michael J. Loiacono As Chief Financial Officer

Accomplished Financial Director & CFO of Public Companies

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

TapImmune Appoints Frederick G. Wasserman To Its Board Of Directors

TapImmune Appoints Frederick G. Wasserman To Its Board Of Directors

Accomplished Financial Director & CFO of Public Companies

U.S. Food & Drug Administration Grants Orphan Drug Designation To TapImmune's TPIV 200 In The Treatment Of Ovarian Cancer

U.S. Food & Drug Administration Grants Orphan Drug Designation To TapImmune's TPIV 200 In The Treatment Of Ovarian Cancer

Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial